CG
IRLA

Cutler Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Cutler Group’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26
Closed -$3K – 4530
2022
Q4 		$3K Sell
26
-28
-52% -$4.68K ﹤0.01% 3516
2022
Q3 		$14K Buy
54
+19
+54% +$7.24K ﹤0.01% 2886
2022
Q2 		$15K Buy
35
+32
+1,067% +$22.6K ﹤0.01% 2914
2022
Q1 		$3K Sell
3
-32
-91% -$43.5K ﹤0.01% 4511
2021
Q4 		$89K Buy
+35
New +$214K ﹤0.01% 1935

Other funds holding IRLA

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cutler Group's IRLA Position: Q1 2023 in Review

Cutler Group sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2023, closing a stake of 26 shares — an estimated $3K sold.

Cutler Group first reported a position in IRLA in Q4 2021 and held it in 5 quarters. The position peaked at $89K in Q4 2021. 42 funds tracked by Wall St. Rank hold IRLA as of Q1 2023.

  • Cutler Group reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 26 IRulya Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $3K.
  • Cutler Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 5 quarters.
  • Cutler Group's IRulya Therapeutics Inc. Common Stock position peaked at $89K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.